Avadel Pharmaceuticals PLC at SVB Leerink Global Healthcare (Virtual) Transcript
Welcome back, everybody, to the next session at the SVB Leerink Healthcare Conference, I'm Marc Goodman, one of the biopharma analysts. And we're lucky enough to have Avadel join us. And we have their CEO, Greg Divis, who's been CEO for the past few years. And obviously, this is a company where -- they have one product that is at FDA and everybody is eagerly waiting for this approval or to hear what's going on. And so, Greg, I guess you got to start with that. So I'll give you some time for opening comments, but you got to tell us where we are and what's happening.
Yes. Thanks, Marc. First of all, thanks for the opportunity to be here and to update everybody on where we are today and really -- and all the exciting opportunities that we see in front of us as we continue this transformation of Avadel we've been on for the last few years here.
As it relates to the NDA, there's been a
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
